Background: Adalimumab first launched in China in August 2010 with more than 10 million people having its indications. However, the relative high cost of the biologic drug limits the treatment accessibility and reduces the quality of life in patients living with the chronic inflammatory disease like rheumatoid arthritis and psoriasis. In accordance with the China National Medical Product Administration (NMPA) biosimilar regulatory development pathway, biosimilar products require to demonstrate similarity in pharmacokinetics (PK) and safety profile compared to its reference drug, which could further address the unmet medical needs of adalimumab. HLX03 was developed as a proposed biosimilar to adalimumab with the potential to increase affordable treatment options for patients.

Objectives: The study was aiming to compare the pharmacokinetics (PK), safety and immunogenicity of the proposed adalimumab biosimilar HLX03 with reference product.

Methods: We conducted a randomised, double-blind, parallel-controlled clinical trial (NCT03316781) in China to compare the PK, safety and immunogenicity of HLX03 and China sourced adalimumab (CN-adalimumab). In this study, 211 healthy volunteers were randomised 1:1 to receive a single (40 mg) subcutaneous injection of HLX03 or CN-adalimumab. The primary PK endpoint area under the curve (AUC) from time zero to the last quantifiable concentration (AUC0-τ) and maximum observed concentration (Cmax) secondary endpoint was AUC from time zero to infinity (AUC0-∞). PK equivalence was established if the 90% confidence interval (CI) for the test-to-reference ratio fall within the 80-125% equivalence margin.

Results: Based on the analysis of 210 subjects in the per protocol population (PPS) and 211 subjects in the full analysis set (FAS), HLX03 demonstrated PK equivalence to CN-adalimumab for all primary endpoints (Table 1). The incidents of adverse events (AEs) between two treatment groups were similar, with treatment-emergent AEs (TEAEs) noted by a total of 149 (70.0%), 79 (73.8%) in HLX03 and 70 (66.0%) in CN-adalimumab group, respectively. One subject suffered non-drug-related severe AE (tuberculosis) in the HLX03 arm, and one subject occurred grade 4 AE (elevated creatine phosphokinase) in the CN-adalimumab arm. In the group of CN-adalimumab, 6 more incidents of positive anti-drug antibodies (ADA) recorded at day 7 and no further significant difference observed. Based on the established clinical PK equivalence and safety similarities, 262 patients with moderate-to-severe chronic plaque psoriasis were randomized in 21 centers at 1:1 ratio to conduct a double-blind, parallel-controlled phase 3 study (NCT03316781) to further evaluate the efficacy and safety profiles of HLX03 and reference adalimumab. The primary efficacy endpoint was the improvement rate of Psoriasis Area and Severity Index (PASI) over the baseline at week 16.

Conclusion: PK equivalence and safety similarities between HLX03 and CN-adalimumab were demonstrated which leads to a multi-center, randomised, double-blind, parallel-controlled phase 3 study to further evaluate the efficacy and safety of HLX03 as the proposed biosimilar of adalimumab in patients with moderate-to-severe plaque psoriasis.

REFERENCES:

were positive for antidrug antibodies (ADAs) in refADL switched and SDZ-ADL groups, respectively. Of these, 81.0 vs 72.2% were neutralizing. ADA positivity had no clinically meaningful impact on safety.

**Conclusion:** After the switch from reference to biosimilar, the rates of EULAR remission/response and Boolean remission were high and maintained until Week 52. Treatment switch from refADL to SDZ-ADL at Wk 24 did not impact efficacy, safety, or immunogenicity.

**REFERENCE:**


**Disclosure of Interests:** Piotr Willand Speakers bureau: Novartis, Pfizer, Abbvie, Gedeon-Richter, Lilly, Roche and Sandoz, Slawomir Jeka: None declared, Eva Dokoupilova: None declared, Juan Manuel Miranda Limon: None declared, Julia Jauch-Lembach Employee of: Hexal AG, Anjali Thakur Employee of: Hexal AG, Halimuniyazi Haliduola Employee of: Hexal AG, Norman Gaylis Grant/research support from: Multiple clinical research trials, BMS, AbbVie, GSK, Janssen, Amgen, Pfizer, Regeneron, UCB, Sanofi, SetPoint, ImmunPharma, Astra Zeneca, Sandoz, Novartis, Gilead, Consultant for: electroCore

**DOI:** 10.1136/annrheumdis-2019-eular.960

---

**SAFETY, IMMUNOGENICITY AND EFFICACY OF THE PROPOSED BIOSIMILAR MSB11022 (MODIFIED FORMULATION) COMPARED WITH ADALUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS: AURIEL-RA, A RANDOMISED, DOUBLE-BLIND, PHASE III STUDY**

Christopher Edwards1, Veronica Chyrok2, Joëlle Monnet2, Martin Ullmann2, Marzena Olesińska1, Anna Felis-Giemza1, Marek Chojnowski2, Julita Rejmer1, Leszek Królicki2, Piotr Wiland

**Background:** Adalimumab is a fully human anti-TNF monoclonal antibody indicated for the treatment of multiple inflammatory disorders, including rheumatoid arthritis (RA). MSB11022 is a proposed adalimumab biosimilar that has been shown to be structurally and functionally similar to the adalimumab reference product. MSB11022 has been developed in two formulations, in a citrate-based buffer, and in a modified buffer and stabiliser. MSB11022 demonstrated bioequivalence and comparable safety, tolerability and immunogenicity profiles to reference adalimumab (both in citrate formulations) in a study in healthy volunteers. Subsequently MSB11022 was shown to be therapeutically equivalent to reference adalimumab both in citrate formulations in terms of efficacy, safety and immunogenicity in psoriasis patients in the 52-week, Phase III, pivotal AURIEL-RA study, in the double-blind, multicentre, phase III AURIEL-RA study (NCT03052322). Safety, efficacy and immunogenicity endpoints were assessed at scheduled visits up to week 52 using descriptive statistical methods only. Safety was the primary objective and the study was not powered to demonstrate equivalent efficacy.

**Methods:** RA patients receiving methotrexate were randomised 1:1 to MSB11022 (modified formulation) or reference adalimumab (citrate formulation) in an additional healthy volunteer study (EMR200588-003). Objectives: To evaluate safety, immunogenicity and efficacy of MSB11022 (modified formulation) in patients with moderately to severe rheumatoid arthritis compared to reference adalimumab up to 52 weeks.

**Results:** 288 RA patients were randomised (MSB11022, n = 143; reference adalimumab, n = 145). Patient baseline characteristics were comparable between treatment groups. Few adverse events of special interest (AESIs) of hypersensitivity (primary endpoint) were reported during the study and the proportions were similar across treatment arms. Efficacy endpoints, including the key secondary endpoint of American College of Rheumatology criteria 20% (ACR20) response rate at week 12, were similar between the treatment arms. The safety profiles of patients receiving MSB11022 and reference adalimumab were also similar through to week 52. There were no clinically meaningful differences in the incidence of anti-drug antibodies (ADAs) and neutralising antibodies (nAbs) between treatment arms up to week 52. Key results are presented in Table 1.

**Conclusion:** MSB11022 (modified formulation) and reference adalimumab had similar safety, immunogenicity and efficacy profiles over 52 weeks in patients with RA, supplementing the clinical data collected with MSB11022 (citrate formulation) in healthy volunteers and psoriasis patients.

**REFERENCE:**


**Disclosure of Interests:** Christopher Edwards Grant/research support from: Abbvie, BMS, Biogen, Celgene, Fresenius, Janssen, Lilly, Mundipharma, Pfizer, MSD, Novartis, Roche, Samsung, Sanofi, UCB, Consultant for: Abbvie, BMS, Biogen, Celgene, Fresenius, Janssen, Lilly, Mundipharma, Pfizer, MSD, Novartis, Roche, Samsung, Sanofi, UCB, Speakers bureau: Abbvie, BMS, Biogen, Celgene, Fresenius, Janssen, Lilly, Mundipharma, Pfizer, MSD, Novartis, Roche, Samsung, Sanofi, UCB, Veronica Chyrok Employee of: Former employee of Fresenius Kabi SwissBioSim, Jodie Monnet Employee of: Employee of Fresenius Kabi SwissBioSim, Martin Ullmann Shareholder of: Amgen, BMS, Employee of: Employee of Fresenius Kabi SwissBioSim, Pan telis Vlachos: None declared

**DOI:** 10.1136/annrheumdis-2019-eular.4220

---

**SAFETY AND EFFICACY OF RADIONUCLIDE SYNOVECTOMY IN PATIENTS WITH PERSISTENT INFLAMMATORY OF SINGLE JOINT IN THE COURSE OF BIOLOGICAL THERAPY**

Anna Felis-Giemza1, Marek Chojnowski2, Julita Rejmer1, Leszek Królicki2, Marzena Oleśińska1, National Institute of Geriatrics, Rheumatology and Rehabilitation, Connective Tissue Diseases Department, Warsaw, Poland; Public Central Teaching Hospital, Nuclear Medicine Department, Warsaw, Poland

**Background:** Radionuclide synovectomy (RVS) is a form of minimally invasive treatment of persistent joint inflammation. Primary indication for RVS is hypertrophic synovitis refractory to disease-modifying anti-rheumatic drugs (DMARDs), whether synthetic or biological, and intraarticular steroid injections. This procedure has a high rate of success with a low rate of adverse events and complications in properly selected patients. Moreover, due to lack of side effects or the radioisotopes, the risk of infection after RSV is insignificant, and incidence of post-injection septic arthritis is extremely low.

**Objectives:** To assess safety and efficacy of RVS in patients with inflammatory rheumatic diseases treated with biological disease-modifying anti-rheumatic drugs (bDMARDs).

**Methods:** We analyzed outcomes of 76 radionuclide synovectomy interventions in 47 patients (37 female and 10 male) ongoing biological therapy. The patients were diagnosed as follows: rheumatoid arthritis (RA) – 37, ankylosing spondylitis (AS) – 7, psoriatic arthritis (PsA) – 2 and juvenile idiopathic arthritis (JIA) – 1 patient. The majority of the patients were treated with TNF-alpha inhibitors (75%), which included: adalimumab (31.6%), etanercept (25%), golimumab (14.5%) and certolizumab (7.9%). The other patients were treated with interleukin-6 receptor antagonist tocilizumab (19.7%) and anti-CDS20 monoclonal antibody rituximab (1.3%). Patients with overall good response to biologics and persistent inflammation of single joint confirmed by ultrasound PD examination, in case of no contraindications were qualified for RSV procedure. For the RSV folow-ing radiotherapeutics were used: rhenium-186 sulphide in 41 cases for shoulder (2), elbow (13), wrist (22), hip (2) and ankle (2) joints; yttrium-90 citrate in 27 cases for knee joints; erbium-169 citrate in 8 cases for small joints of hand and feet. All patients had a follow-up visit 3 and 6 months after RSV, during which a clinical and ultrasound examination of the treated joints were performed. Continuous adverse events collection was conducted.

**Results:** The most common indication for RSV was RA – 60 procedures (78.9%), followed by AS – 10 (13.2%), PsA – 4 (5.3%) and JIA – 1 procedure (2.6%). 27 patients had RSV intervention in one joint. 17